Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Core Insights - Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a peripherally restricted CB1 inverse agonist aimed at treating obesity, following the single ascending dose (SAD) study [2][4] - The MAD study is designed to assess the safety, tolerability, and pharmacokinetics of CRB-913 with a once-daily dosing regimen over 7 days in healthy volunteers [3][4] - Preliminary data from the SAD study indicates no treatment-related neuropsychiatric events, even at higher doses than expected for efficacy [4][5] Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, with a pipeline that includes CRB-701, CRB-601, and CRB-913 [6] - CRB-913 is characterized as an oral small molecule inverse agonist of the CB1 receptor, designed to minimize brain penetration and reduce the risk of neuropsychiatric side effects compared to previous drugs in this class [5][6] - The company is headquartered in Norwood, Massachusetts, and aims to leverage innovative scientific approaches to address serious illnesses [6]